BioAtla Files 2024 10-K, Details BeiGene Deal
Ticker: BCAB · Form: 10-K · Filed: Mar 28, 2025 · CIK: 1826892
Sentiment: neutral
Topics: 10-K, biotech, collaboration, financials
TL;DR
BioAtla's 2024 10-K is out. Shows BeiGene deal details and equity comp. #biotech
AI Summary
BioAtla, Inc. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its operations and financial condition. The company's business address is 11085 Torreyana Road, San Diego, CA 92121. Key events and financial data from the filing include details on equity-based compensation, common stock warrants, and the amended BeiGene collaboration as of December 31, 2023.
Why It Matters
This filing provides investors with a comprehensive overview of BioAtla's financial health and strategic partnerships for the past fiscal year, including updates on significant collaborations like the one with BeiGene.
Risk Assessment
Risk Level: medium — Biotech companies often carry higher risk due to the nature of drug development, regulatory hurdles, and market competition.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the reporting period for the 10-K.)
- 20250328 — Filing Date (The date the 10-K was officially submitted to the SEC.)
- 001-39787 — SEC File Number (Unique identifier for BioAtla's filings with the SEC.)
Key Players & Entities
- BioAtla, Inc. (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 11085 Torreyana Road, San Diego, CA 92121 (address) — Company business address
- BeiGene (company) — Partner in an amended collaboration
- 2023-12-31 (date) — Date related to BeiGene collaboration and equity-based compensation
FAQ
What is the primary business of BioAtla, Inc. according to the filing?
BioAtla, Inc. is primarily involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
When was the BeiGene collaboration amended, and what is its status as of the filing date?
The BeiGene collaboration was amended as of November 18, 2021, and details related to this amended collaboration are reported as of December 31, 2023.
What type of compensation is mentioned in the filing related to employees?
The filing mentions 'EquityBasedCompensation' and 'EmployeesStockPurchasePlan' as relevant financial items.
What is the company's state of incorporation?
BioAtla, Inc. is incorporated in Delaware (DE).
What are the reported operating segments or expense categories mentioned?
The filing references 'OperatingSegmentsMember', 'TotalProgramExpensesMember', and 'FacilitiesAndOther'.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 28, 2025 regarding BioAtla, Inc. (BCAB).